Genetic association studies in drug-induced liver injury

References

• Acuna, G., Foernzler, D., Leong, D., Rabbia, M., Smit, R., Dorflinger, E., et al. (2002). Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. Pharmacogenomics J 2:327–334.
   PubMedGoogle Scholar
• Adam, J., Pichler, W. J., Yerly, D. (2011). Delayed drug hypersensitivity: models of T-cell stimulation. Br J Clin Pharmacol 71:701–707.
   PubMed Web of Science ®Google Scholar
• Aithal, G. P., Day, C. P., Leathart, J. B. S., Daly, A. K. (2000). Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 10:511–518.
   PubMedGoogle Scholar
• Aithal, G. P., Ramsay, L., Daly, A. K., Sonchit, N., Leathart, J. B., Alexander, G., et al. (2004). Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology 39:1430–1440.
   PubMed Web of Science ®Google Scholar
• Aithal, G. P., Rawlins, M. D., Day, C. P. (1999). Accuracy of hepatic adverse drug reaction reporting in one English health region. Br Med J 319:1541–1541.
   PubMed Web of Science ®Google Scholar
• Andrade, R. J., Lucena, M. I., Alonso, A., Garcia-Cortes, M., Garcia-Ruiz, E., Benitez, R., et al. (2004). HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology 39:1603–1612.
   PubMed Web of Science ®Google Scholar
• Andrews, E., Armstrong, M., Tugwood, J., Swan, D., Glaves, P., Pirmohamed, M., et al. (2010). A role for the pregnane X receptor in flucloxacillin-induced liver injury. Hepatology 51:1656–1664.
   PubMed Web of Science ®Google Scholar
• Becquemont, L. (2010). HLA: a pharmacogenomics success story. Pharmacogenomics 11:277–281.
   PubMed Web of Science ®Google Scholar
• Berson, A., Freneaux, E., Larrey, D., Lepage, V., Douay, C., Mallet, C., et al. (1994). Possible role of HLA in hepatotoxicity—an exploratory-study in 71 patients with drug-induced idiosyncratic hepatitis. J Hepatol 20:336–342.
   PubMed Web of Science ®Google Scholar
• Bhatnagar, P., Day, C. P., Aithal, G., Pirmohamed, M., Bernal, W., Daly, A. K. (2008). Genetic variants of hepatic transporters and susceptibility to drug induced liver injury. Toxicology 253:10.
   Web of Science ®Google Scholar
• Bjornsson, E. (2009). The natural history of drug-induced liver injury. Semin Liver Dis 29:357–363.
   PubMed Web of Science ®Google Scholar
• Bourdi, M., Eiras, D. P., Holt, M. P., Webster, M. R., Reilly, T. P., Welch, K. D., et al. (2007). Role of IL-6 in an IL-10 and IL-4 double knockout mouse model uniquely susceptible to acetaminophen-induced liver injury. Chem Res Toxicol 20:208–216.
   PubMed Web of Science ®Google Scholar
• Bourdi, M., Masubuchi, Y., Reilly, T. P., Amouzadeh, H. R., Martin, J. L., George, J. W., et al. (2002). Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. Hepatology 35:289–298.
   PubMed Web of Science ®Google Scholar
• Bozok Cetintas, V., Erer, O. F., Kosova, B., Ozdemir, I., Topcuoglu, N., Aktogu, S., et al. (2008). Determining the relation between N-acetyltransferase-2 acetylator phenotype and antituberculosis drug induced hepatitis by molecular biologic tests. Tuberk Toraks 56:81–86.
   PubMedGoogle Scholar
• Carr, D. F., Alfirevic, A., Tugwood, J. D., Barratt, B. J., Sherwood, J., Smith, J., et al. (2007). Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity. Pharmacogenet Genomics 17:961–972.
   PubMed Web of Science ®Google Scholar
• Chen, P., Lin, J. J., Lu, C. S., Ong, C. T., Hsieh, P. F., Yang, C. C., et al. (2011). Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med 364:1126–1133.
   PubMed Web of Science ®Google Scholar
• Cho, H. J., Koh, W. J., Ryu, Y. J., Ki, C. S., Nam, M. H., Kim, J. W., et al. (2007). Genetic polymorphisms of NAT2 and CYP2E1 associated with antituberculosis drug-induced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb) 87:551–556.
   PubMed Web of Science ®Google Scholar
• Choi, J. H., Ahn, B. M., Yi, J., Lee, J. H., Nam, S. W., Chon, C. Y., et al. (2007). MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics 17:403–415.
   PubMed Web of Science ®Google Scholar
• Chung, W. H., Hung, S. I., Hong, H. S., Hsih, M. S., Yang, L. C., Ho, H. C., et al. (2004). Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428:486.
   PubMed Web of Science ®Google Scholar
• Daly, A. K. (2004). Pharmacogenetics of the cytochromes P450. Curr Top Med Chem 4:1733–1744.
   PubMed Web of Science ®Google Scholar
• Daly, A. K., Aithal, G. P., Leathart, J. B., Swainsbury, R. A., Dang, T. S., Day, C. P. (2007). Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132:272–281.
   PubMed Web of Science ®Google Scholar
• Daly, A. K., Donaldson, P. T., Bhatnagar, P., Shen, Y., Pe’er, I., Floratos, A., et al. (2009). HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 41:816–819.
   PubMed Web of Science ®Google Scholar
• Deng, X., Stachlewitz, R. F., Liguori, M. J., Blomme, E. A., Waring, J. F., Luyendyk, J. P., et al. (2006). Modest inflammation enhances diclofenac hepatotoxicity in rats: role of neutrophils and bacterial translocation. J Pharmacol Exp Ther 319:1191–1199.
   PubMed Web of Science ®Google Scholar
• Dickinson, D. S., Bailey, W. C., Hirschowitz, B. I., Soong, S. J., Eidus, L., Hodgkin, M. M. (1981). Risk factors for isoniazid (NIH)-induced liver dysfunction. J Clin Gastroenterol 3:271–279.
   PubMed Web of Science ®Google Scholar
• Donaldson, P. T., Daly, A. K., Henderson, J., Graham, J., Pirmohamed, M., Bernal, W., et al. (2010). Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol 53:1049–1053.
   PubMed Web of Science ®Google Scholar
• Durbin, R. M., Abecasis, G. R., Altshuler, D. L., Auton, A., Brooks, L. D., Durbin, R. M., et al. (2010). A map of human genome variation from population-scale sequencing. Nature 467:1061–1073.
   PubMed Web of Science ®Google Scholar
• Eichelbaum, M., Musch, E., Castroparra, M., Vonsassen, W. (1982). Isoniazid hepatotoxicity in relation to acetylator phenotype and isoniazid metabolism. Br J Clin Pharmacol 14:P575–P576
   Web of Science ®Google Scholar
• Fontana, R. J., Seeff, L. B., Andrade, R. J., Bjornsson, E., Day, C. P., Serrano, J., et al. (2010). Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 52:730–742.
   PubMedGoogle Scholar
• Fontana, R. J., Watkins, P. B., Bonkovsky, H. L., Chalasani, N., Davern, T., Serrano, J., et al. (2009). Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design, and conduct. Drug Saf 32:55–68.
   PubMed Web of Science ®Google Scholar
• Geier, A., Wagner, M., Dietrich, C. G., Trauner, M. (2007). Principles of hepatic organic anion transporter regulation during cholestasis, inflammation, and liver regeneration. Biochim Biophys Acta 1773:283–308.
   Google Scholar
• Gronhagen-Riska, C., Hellstrom, P. E., Froseth, B. (1978). Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis. Am Rev Respir Dis 118:461–466.
   PubMed Web of Science ®Google Scholar
• Grove, J., Daly, A. K., Bassendine, M. F., Day, C. P. (1997). Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 26:143–146.
   PubMed Web of Science ®Google Scholar
• Grove, J., Daly, A. K., Bassendine, M. F., Gilvarry, E., Day, C. P. (2000). Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut 46:540–545.
   PubMed Web of Science ®Google Scholar
• Haas, D. W., Bartlett, J. A., Andersen, J. W., Sanne, I., Wilkinson, G. R., Hinkle, J., et al. (2006). Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis 43:783–786.
   PubMed Web of Science ®Google Scholar
• Haenisch, S., Zimmermann, U., Dazert, E., Wruck, C. J., Dazert, P., Siegmund, W., et al. (2007). Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex. Pharmacogenomics J 7:56–65.
   PubMed Web of Science ®Google Scholar
• Hautekeete, M. L., Horsmans, Y., Van Waeyenberge, C., Demanet, C., Henrion, J., Verbist, L., et al. (1999). HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology 117:1181–1186.
   PubMed Web of Science ®Google Scholar
• Hayashi, S., Watanabe, J., Kawagiri, K. (1991). Genetic polymorphisms in the 5′-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene. J Biochem 110:559–565.
   PubMed Web of Science ®Google Scholar
• Hirata, K., Takagi, H., Yamamoto, M., Matsumoto, T., Nishiya, T., Mori, K., et al. (2008). Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J 8:29–33.
   PubMed Web of Science ®Google Scholar
• Huang, Y. S., Chern, H. D., Su, W. J., Wu, J. C., Chang, S. C., Chiang, C. H., et al. (2003). Cytochrome p450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 37:924–930.
   PubMed Web of Science ®Google Scholar
• Huang, Y. S., Chern, H. D., Su, W. J., Wu, J. C., Lai, S. L., Yang, S. Y., et al. (2002). Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35:883–889.
   PubMed Web of Science ®Google Scholar
• Huang, Y. S., Su, W. J., Huang, Y. H., Chen, C. Y., Chang, F. Y., Lin, H. C., et al. (2007). Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J Hepatol 47:128–134.
   PubMed Web of Science ®Google Scholar
• Kaplowitz, N. (2005). Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov 4:489–499.
   PubMed Web of Science ®Google Scholar
• Kato, S., Shields, P. G., Caporaso, N. E., Hoover, R. N., Trump, B. F., Sugimura, H., et al. (1992). Cytochrome P450IIE1 genetic polymorphisms, racial variation, and lung cancer risk. Cancer Res 52:6712–6715.
   PubMed Web of Science ®Google Scholar
• Kim, S. H., Kim, S. H., Bahn, J. W., Kim, Y. K., Chang, Y. S., Shin, E. S., et al. (2009). Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics 10:1767–1779.
   PubMed Web of Science ®Google Scholar
• Kindmark, A., Jawaid, A., Harbron, C. G., Barratt, B. J., Bengtsson, O. F., Andersson, T. B., et al. (2008). Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 8:186–195.
   PubMed Web of Science ®Google Scholar
• Kuhlenbaumer, G., Hullmann, J., Appenzellerm, S. (2011). Novel genomic techniques open new avenues in the analysis of monogenic disorders. Hum Mutat 32:144–151.
   PubMed Web of Science ®Google Scholar
• Lang, C., Meier, Y., Stieger, B., Beuers, U., Lang, T., Kerb, R., et al. (2007). Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics 17:47–60.
   PubMed Web of Science ®Google Scholar
• Lee, S. W., Chung, L. S., Huang, H. H., Chuang, T. Y., Liou, Y. H., Wu, L. S. (2010). NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis 14:622–626.
   PubMed Web of Science ®Google Scholar
• Leiro, V., Fernandez-Villar, A., Valverde, D., Constenla, L., Vazquez, R., Pineiro, L., et al. (2008). Influence of glutathione S-transferase M1 and T1 homozygous null mutations on the risk of antituberculosis drug-induced hepatotoxicity in a Caucasian population. Liver Int 28:835–839.
   PubMed Web of Science ®Google Scholar
• Lonjou, C., Thomas, L., Borot, N., Ledger, N., De Toma, C., Lelouet, H., et al. (2006). A marker for Stevens-Johnson syndrome...: ethnicity matters. Pharmacogenomics J 6:265–268.
   PubMed Web of Science ®Google Scholar
• Lucena, M. I., Andrade, R. J., Martinez, C., Ulzurrun, E., Garcia-Martin, E., Borraz, Y., et al. (2008). Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 48:588–596.
   PubMed Web of Science ®Google Scholar
• Lucena, M. I., Garcia-Martin, E., Andrade, R. J., Martinez, C., Stephens, C., Ruiz, J. D., et al. (2010). Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology 52:303–312.
   PubMed Web of Science ®Google Scholar
• Lucena, M. I., Molokhia, M., Shen, Y., Urban, T. J., Aithal, G. P., Andrade, R. J., et al. (2011). Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 141:338–347.
   PubMed Web of Science ®Google Scholar
• Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A. M., Moore, C., et al. (2002). Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 359:727–732.
   PubMed Web of Science ®Google Scholar
• Mallal, S., Phillips, E., Carosi, G., Molina, J. M., Workman, C., Tomazic, J., et al. (2008). HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 358:568–579.
   PubMed Web of Science ®Google Scholar
• Martin, A. M., Nolan, D., James, I., Cameron, P., Keller, J., Moore, C., et al. (2005). Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. Aids 19:97–99.
   PubMed Web of Science ®Google Scholar
• McCormack, M., Alfirevic, A., Bourgeois, S., Farrell, J. J., Kasperaviciute, D., Carrington, M., et al. (2011). HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 364:1134–1143.
   PubMed Web of Science ®Google Scholar
• Metushi, I. G., Cai, P., Zhu, X., Nakagawa, T., Uetrecht, J. P. (2011). A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther 89:911–914.
   PubMed Web of Science ®Google Scholar
• Mitchell, J. R., Thorgeirsson, U. P., Black, M., Timbrell, J. A., Snodgrass, W. R., Potter, W. Z., et al. (1975). Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther 18:70–79.
   PubMed Web of Science ®Google Scholar
• Mitchell, J. R., Zimmerman, H. J., Ishak, K. G., Thorgeisson, U. P., Timbrell, J. A., Snodgrass, W. R., et al. (1976). Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med 84:181–192.
   PubMed Web of Science ®Google Scholar
• Molokhia, M., Mckeigue, P. (2006). EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions. Pharmacogenomics 7:633–638.
   PubMed Web of Science ®Google Scholar
• Noe, J., Kullak-Ublick, G. A., Jochum, W., Stieger, B., Kerb, R., Haberl, M., et al. (2005). Impaired expression and function of the bile salt export pump due to three novel ABCB11 mutations in intrahepatic cholestasis. J Hepatol 43:536–543.
   PubMed Web of Science ®Google Scholar
• O’Donohue, J., Oien, K. A., Donaldson, P., Underhill, J., Clare, M., Macsween, R. M., et al. (2000). Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 47:717–720.
   PubMed Web of Science ®Google Scholar
• Ohno, M., Yamaguchi, I., Yamamoto, I., Fukuda, T., Yokota, S., Maekura, R., et al. (2000). Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 4:256–261.
   PubMed Web of Science ®Google Scholar
• Ozeki, T., Mushiroda, T., Yowang, A., Takahashi, A., Kubo, M., Shirakata, Y., et al. (2011). Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 20:1034–1041.
   PubMed Web of Science ®Google Scholar
• Pachkoria, K., Lucena, M. I., Crespo, E., Ruiz-Cabello, F., Lopez-Ortega, S., Fernandez, M. A., et al. (2008). Analysis of IL-10, IL-4, and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome. J Hepatol 49:107–114.
   PubMed Web of Science ®Google Scholar
• Pachkoria, K., Lucena, M. I., Ruiz-Cabello, F., Crespo, E., Cabello, M. R., Andrade, R. J. (2007). Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br J Pharmacol 150:808–815.
   PubMed Web of Science ®Google Scholar
• Possuelo, L. G., Castelan, J. A., De Brito, T. C., Ribeiro, A. W., Cafrune, P. I., Picon, P. D., et al. (2008). Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from Southern Brazil. Eur J Clin Pharmacol 64:673–681.
   PubMed Web of Science ®Google Scholar
• Ritchie, M. D., Haas, D. W., Motsinger, A. A., Donahue, J. P., Erdem, H., Raffanti, S., et al. (2006). Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis 43:779–782.
   PubMed Web of Science ®Google Scholar
• Roy, B., Chowdhury, A., Kundu, S., Santra, A., Dey, B., Chakraborty, M., et al. (2001). Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 “null” mutation. J Gastroenterol Hepatol 16:1033–1037.
   PubMed Web of Science ®Google Scholar
• Russmann, S., Kaye, J. A., Jick, S. S., Jick, H. (2005). Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK General Practice Research Database. Br J Clin Pharmacol 60:76–82.
   PubMed Web of Science ®Google Scholar
• Saukkonen, J. J., Cohn, D. L., Jasmer, R. M., Schenker, S., Jereb, J. A., Nolan, C. M., et al. (2006). An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 174:935–952.
   PubMed Web of Science ®Google Scholar
• Sgro, C., Clinard, F., Ouazir, K., Chanay, H., Allard, C., Guilleminet, C., et al. (2002). Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36:451–455.
   PubMed Web of Science ®Google Scholar
• Sharma, S. K., Balamurugan, A., Saha, P. K., Pandey, R. M., Mehra, N. K. (2002). Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am J Respir Crit Care Med 166:916–919.
   PubMed Web of Science ®Google Scholar
• Singer, J. B., Lewitzky, S., Leroy, E., Yang, F., Zhao, X., Klickstein, L., et al. (2010). A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 42:711–714.
   PubMed Web of Science ®Google Scholar
• Spraggs, C. F., Budde, L. R., Briley, L. P., Bing, N., Cox, C. J., King, K. S., et al. (2011). HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 29:667–673.
   PubMed Web of Science ®Google Scholar
• Stewart, J. D., Horvath, R., Baruffini, E., Ferrero, I., Bulst, S., Watkins, P. B., et al. (2010). Polymerase gamma gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology 52:1791–1796.
   PubMed Web of Science ®Google Scholar
• Stricker, B. H., Blok, A. P., Claas, F. H., Van Parys, G. E., Desmet, V. J. (1988). Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology 8:599–606.
   PubMed Web of Science ®Google Scholar
• Uetrecht, J. (2009). Immunoallergic drug-induced liver injury in humans. Semin Liver Dis 29:383–392.
   PubMed Web of Science ®Google Scholar
• Urban, T., Shen, Y. F., Chalasani, N. P., Fontana, R. J., Rochon, J., Stolz, A., et al. (2011). A genome-wide association study identifies potential susceptibility loci for hepatotoxicity due to various drugs. Gastroenterology 140:S886–S886
   Web of Science ®Google Scholar
• Vuilleumier, N., Rossier, M. F., Chiappe, A., Degoumois, F., Dayer, P., Mermillod, B., et al. (2006). CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 62:423–429.
   PubMedGoogle Scholar
• Watanabe, I., Tomita, A., Shimizu, M., Sugawara, M., Yasumo, H., Koishi, R., et al. (2003). A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther 73:435–455.
   PubMed Web of Science ®Google Scholar
• Xu, C. F., Reck, B. H., Goodman, V. L., Xue, Z., Huang, L., Barnes, M. R., et al. (2010). Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma. J Hepatol 54:1237–1243.
   Web of Science ®Google Scholar
• Yamada, S., Tang, M., Richardson, K., Halaschek-Wiener, J., Chan, M., Cook, V. J., et al. (2009). Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics 10:1433–1445.
   PubMed Web of Science ®Google Scholar
• Yee, S. B., Bourdi, M., Masson, M. J., Pohl, L. R. (2007). Hepatoprotective role of endogenous interleukin-13 in a murine model of acetaminophen-induced liver disease. Chem Res Toxicol 20:734–744.
   PubMed Web of Science ®Google Scholar
• Yuan, J., Guo, S., Hall, D., Cammett, A. M., Jayadev, S., Distel, M., et al. (2011). Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS 25:1271–1280.
   PubMed Web of Science ®Google Scholar